# Table of Contents

## Primary Prevention of Cardiovascular Disease and Public Health


## Dyslipidemia

Role of Lipoproteins in Development of ASCVD, Risk Assessment for Primary Prevention, Review of Current Practice Guidelines, Statin Therapy, Non-Statin Therapies; Strategies in Specific Patient Populations.

## Anticoagulation


## Stable Atherosclerotic Disease

Stable Ischemic Heart Disease: Pathophysiology, Clinical Presentation, Classification, Diagnostic Procedures, Goals of Treatment, Pharmacologic Therapies (antiplatelet, antianginal), Nonpharmacologic Therapies (PCI, CABG); Secondary Prevention of Atherosclerotic Stroke or Transient Ischemic Attack, Peripheral Arterial Disease Screening and Treatment.

## Pulmonary Arterial Hypertension

Classification, Risk Factors, Pathophysiology, Clinical Presentation, Diagnosis, Risk Assessment, Treatment Goals, Pharmacologic Therapy Options, Selecting Therapy in Specific Patient Populations.

## Principles of Information Management and Education: Research Design, Biostatistics, and Literature Evaluation, and Education and Training

Cardiovascular Literature Sources, Biostatistical Methods Used in Cardiovascular Trials, Choosing the Most Appropriate Statistical Test, Interpreting Statistical Data, Correlation, Regression and Survival Analysis, Research Design and Methodology, Determining Internal and External Validity, Cardiovascular Study Endpoints, Disseminating Cardiovascular Knowledge, Patient Education Techniques, Educating, Training and Mentoring Pharmacy Trainees and Practicing Pharmacists.
### Table of Contents

#### Specialized Topics in Cardiovascular Disease .......................... 231

*Infective Endocarditis (Prevention, Common Pathogens, Treatment, Role of Antithrombotic Therapy); Pericarditis (Diagnosis, Classification, Treatment, Special Pericardial Syndromes); Myocarditis (Diagnosis, Clinical Presentation and Management); Valvular Disorders (Atrial and Ventricular Disorders, Diagnosis, Presentation, Secondary Prevention of Rheumatic Heart Disease in Adults, Symptom-based Guideline Directed Pharmacologic Therapy, Valve Replacement including TAVR, and Antithrombotic Therapy).*

#### Drug-Induced Cardiovascular Disease and Drugs to Avoid in CV Disease ........................................ 271

*Drug-Induced: Supraventricular and Ventricular Arrhythmias, Valvular Disease, Hyper- and Hypotension, Heart Failure, and Myocardial Ischemia; Medications Associated with Increased Cardiovascular Risk; Drugs to Avoid in Specific Populations.*

#### Chronic Heart Failure ........................................ 301

*Classification, Staging, Diagnosis, Role of Biomarkers, Pathophysiology, Pharmacotherapy of Heart Failure with Reduced Ejection Fraction, Device and Sensor Therapy, Pharmacotherapy of Heart Failure with Preserved Ejection Fraction; Important Comorbidities in Heart Failure, Nonpharmacologic Considerations.*

#### Acute Heart Failure ........................................ 373

*Pathophysiology, Clinical Presentation, Hemodynamic Parameters, Role of Biomarkers, Hemodynamic Subsets and Therapy, Diuretic Dosing Strategies, Inotropic Therapies, Vasodilator Therapies.*

#### Cardiac Transplantation and Mechanical Circulatory Support for Advanced Heart Failure .......................... 401

*Criteria for Advanced Heart Failure, Candidacy for Advanced Therapies (Heart Transplant and Durable Left Ventricular Assist Devices [LVAD]), Heart Transplantation (Pre-transplant, Perioperative, and Post-transplant Management), Percutaneous Ventricular Assist Devices, Extracorporeal Membrane Oxygenation, Durable Continuous-Flow LVADs.*

#### Arrhythmias ........................................ 445

*Electrocardiogram Interpretation, Sinus Bradycardia, Atrioventricular Block, Atrial Fibrillation (Rate and Rhythm Control Strategies, Conversion Therapies; Treatment Strategies in Special Populations), Supraventricular Tachycardia, Premature Ventricular Complexes, Ventricular Tachycardia.*

#### Cardiovascular Emergencies ........................................ 525

*Advance Cardiac Life Support Protocols, Targeted Temperature Management, Cardiac Tamponade, Shock Syndromes, Hypertensive Crisis, Acute Aortic Syndrome, and Acute Ischemic Stroke.*
# Table of Contents

**Principles of Practice Administration: Protocol Development and Quality Improvement; Pharmacoeconomics and Safe Medication Use.** ................................................................. 583


**Acute Coronary Syndrome** ................................................................. 635


**Pharmacogenomics of Cardiovascular Therapies** .............................. 685


**Blood Pressure Management in Adult patients** ................................. 707

Classification, Diagnosis, Screening and Management of Risk Factors, Secondary Causes, Blood Pressure Measurement Methods, Setting Blood Pressure Goals, Non-pharmacologic and Pharmacologic Therapy, Treatment in Special Populations, Resistant Hypertension, Hypotension.

**The Board of Pharmacy Specialties “2018 Candidate’s Guide”** .............. 755

Printed courtesy of the Board of Pharmacy Specialties (BPS)